Illumina (ILMN)
(Delayed Data from NSDQ)
$110.62 USD
-2.20 (-1.95%)
Updated May 8, 2024 04:00 PM ET
After-Market: $110.63 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ILMN 110.62 -2.20(-1.95%)
Will ILMN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ILMN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ILMN
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
Illumina (ILMN) Reports Q1 Earnings: What Key Metrics Have to Say
ILMN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
Gear Up for Illumina (ILMN) Q1 Earnings: Wall Street Estimates for Key Metrics
Other News for ILMN
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Illumina (ILMN)
Illumina Unusual Options Activity For May 07
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND), Owens & Minor (OMI) and Illumina (ILMN)
Illumina divestiture of GRAIL would be positive, says Canaccord
Illumina files Form 10 registration statement ahead of planned GRAIL divestiture